1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 176 pages

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 15, 8, 2, 16 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2017
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 8
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 29
Allergan Plc 29
Arisaph Pharmaceuticals Inc 29
AstraZeneca Plc 30
Betagenon AB 30
Bird Rock Bio Inc 31
Can-Fite BioPharma Ltd 31
Cerenis Therapeutics Holding SA 32
Conatus Pharmaceuticals Inc 32
Corcept Therapeutics Inc 33
CymaBay Therapeutics Inc 33
Daewoong Pharmaceutical Co Ltd 34
Dimerix Bioscience Pty Ltd 34
Dr. Falk Pharma GmbH 35
DURECT Corp 35
Enanta Pharmaceuticals Inc 36
Eternygen GmbH 36
Galmed Pharmaceuticals Ltd 37
Gemphire Therapeutics Inc 37
Genfit SA 38
Gilead Sciences Inc 38
Huons Co Ltd 39
Immuron Ltd 39
Kyorin Pharmaceutical Co Ltd 40
Matinas BioPharma Holdings Inc 40
Miyarisan Pharmaceutical Company Ltd 41
NovaTarg Therapeutics Inc 41
Pfizer Inc 42
Renova Therapeutics Inc 42
Sancilio and Company Inc 43
TaiwanJ Pharmaceuticals Co Ltd 43
TCM Biotech International Corp 44
Zydus Cadila Healthcare Ltd 44
Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles 45
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 45
(leucine + PDE5 Inhibitor) - Drug Profile 47
AC-261066 - Drug Profile 48
Aramchol - Drug Profile 49
ARI-3037MO - Drug Profile 55
AZD-4076 - Drug Profile 57
C-10 - Drug Profile 59
CBM-588 - Drug Profile 61
cenicriviroc mesylate - Drug Profile 63
CER-209 - Drug Profile 71
CORT-118335 - Drug Profile 72
dapagliflozin propanediol - Drug Profile 73
DMX-300 - Drug Profile 80
Drug to Antagonize MCJ for Gastrointestinal Disorders - Drug Profile 81
DUR-928 - Drug Profile 82
DWP-10292 - Drug Profile 86
EDP-305 - Drug Profile 87
elafibranor - Drug Profile 88
emricasan - Drug Profile 96
FLB-12 - Drug Profile 104
gemcabene calcium - Drug Profile 105
GS-0976 - Drug Profile 109
GS-9674 - Drug Profile 111
HTD-1801 - Drug Profile 114
HU-002 - Drug Profile 115
IMM-124E - Drug Profile 116
liothyronine sodium - Drug Profile 119
MAT-8800 - Drug Profile 120
MN-002 - Drug Profile 121
naltrexone hydrochloride - Drug Profile 123
Namacizumab - Drug Profile 125
namodenoson - Drug Profile 126
NLM-0100 - Drug Profile 131
norursodeoxycholic acid - Drug Profile 132
O-304 - Drug Profile 134
oltipraz - Drug Profile 136
PF-06835919 - Drug Profile 137
RT-200 - Drug Profile 138
RT-210 - Drug Profile 139
saroglitazar - Drug Profile 140
SC-410 - Drug Profile 142
seladelpar - Drug Profile 143
selonsertib - Drug Profile 147
Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 149
Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease - Drug Profile 150
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 151
Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 152
Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis - Drug Profile 153
TCM-606F - Drug Profile 154
tipelukast - Drug Profile 155
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 160
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 161
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 162
Featured News and Press Releases 162
Appendix 172
Methodology 172
Coverage 172
Secondary Research 172
Primary Research 172
Expert Panel Validation 172
Contact Us 172
Disclaimer 173

List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Allergan Plc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CymaBay Therapeutics Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Genfit SA, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio and Company Inc, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H1 2017
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I) - Pipeline Review, H2 2016

Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative ...

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.